

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-0002

July 2, 2015

Ethicon Incorporated a Johnson & Johnson company Ms. Donna Marshall Manager of Regulatory Affairs P.O. Box 151 Route 22 West Somerville, New Jersey 08876

Re: K150670

Trade/Device Name: STRATAFIX[™] Spiral PDS[™] Plus Knotless Tissue Control Device Regulation Number: 21 CFR 878.4840 Regulation Name: Absorbable polydioxanone surgical suture Regulatory Class: Class II Product Code: NEW Dated: June 4, 2015 Received: June 5, 2015

Dear Ms. Marshall:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<u>http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm</u> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

for

Sincerely yours,

David Krause -S

- Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director
 - Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number *(if known)* K150670

Device Name

STRATAFIX[™] Spiral PDS[™] Plus Knotless Tissue Control Device

Indications for Use (Describe)

STRATAFIXTM Spiral PDSTM Plus Knotless Tissue Control Device is indicated for soft tissue approximation where use of an absorbable suture is appropriate.

Type of Use (Select one or both, as applicable)	
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff *PRAStaff@fda.hhs.gov*

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Traditional 510(k) STRATAFIX™ Spiral PDS™ Plus Knotless Tissue Control Device Ethicon, Inc.

ETHICON, INC.

a Johnson Johnson company

510(k) Summary

Submitter:

Ethicon Inc. a Johnson & Johnson company P.O. Box 151 Route 22 West Somerville, NJ 08876-0151 USA

Contact Person:

Donna Marshall Manager, Regulatory Affairs Ethicon, Inc. a Johnson & Johnson company Ph: (908) 541-3990 Fax: (908) 218-2595 e-mail: <u>dmarsha2@its.jnj.com</u>

Date Prepared:	March 13, 2015
Device Trade Name:	STRATAFIX [™] Spiral PDS [™] Plus Knotless Tissue Control Device
Device Common Name:	Suture, Surgical, Absorbable, Polydioxanone
Class:	П
Classification Name:	Absorbable Polydioxanone Surgical Suture (21 CFR 878.4840)
Product Code:	NEW

Predicate Device	510(k) Number
PDS TM Plus Antibacterial (polydioxanone) Suture	K061037
Quill [™] PDO Knotless Tissue Closure Device, Variable	K123877
	K113744
Loop (polydioxanone)	K132268
Quill [™] PDO Knotless Tissue Closure Device	K120827

Traditional 510(k) STRATAFIX™ Spiral PDS™ Plus Knotless Tissue Control Device Ethicon, Inc.

Device Description:

The STRATAFIXTM Spiral PDSTM *Plus* Device is an antibacterial monofilament, synthetic absorbable device consisting of dyed (violet) polyester, poly(p-dioxanone), the empirical molecular formula of which is $(C_4H_6O_3)_X$. The device contains IRGACARE[®]* MP (triclosan), a broad spectrum antibacterial agent, at no more than 2360 µg/m. The pigment for the violet dye is D&C Violet No. 2. Polydioxanone polymer has been found to be nonallergenic, nonpyrogenic and elicits only a slight tissue reaction during absorption.

The STRATAFIXTM Spiral PDSTM *Plus* Knotless Tissue Control Device, Variable Loop Design consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The STRATAFIXTM Spiral PDSTM *Plus* Device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. The STRATAFIXTM Spiral PDSTM *Plus* Device barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.

While the formation of barbs in the STRATAFIXTM Spiral PDSTM *Plus* Device reduces the tensile strength relative to non-barbed suture material of the same size, tying of knots in non-barbed suture materials also reduces their effective strength. For this reason, the strength of the STRATAFIXTM Spiral PDSTM *Plus* Device can be compared to USP knot strength of non-barbed sutures. Additionally, USP designations for diameter are used to describe the STRATAFIXTM Spiral PDSTM *Plus* Device suture material after barbing, except for minor variation in suture diameter with a maximum overage of 0.1 mm.

Indications for Use:

STRATAFIXTM Spiral PDSTM Plus Knotless Tissue Control Devices are indicated for general soft tissue approximation where use of an absorbable suture is appropriate.

Performance Data:

Non-clinical laboratory performance testing was performed demonstrating that STRATAFIXTM Spiral PDSTM Plus Knotless Tissue Control Device conforms to the current USP Monograph for absorbable surgical sutures, except for diameter. This testing was performed in accordance with FDA's Class II Special Controls Guidance Document: Surgical Sutures, Issued June 3, 2003. In addition, bench and animal testing was provided showing that the device performed as intended and as claimed.

Summary of Technological Characteristics and Performance Testing:

The STRATAFIX[™] Spiral PDS[™] Plus Knotless Tissue Control Device has similar technological characteristics as the predicate devices. Like the currently marketed devices, STRATAFIX[™] Spiral PDS[™] Plus Knotless Tissue Control Device is a sterile, monofilament synthetic absorbable suture intended for the approximation of soft tissue that conforms to the

Traditional 510(k) STRATAFIX™ Spiral PDS™ Plus Knotless Tissue Control Device Ethicon, Inc.

USP Monograph for absorbable surgical sutures, except for diameter. Similar to the currently marketed PDS Plus suture, STRATAFIX[™] Spiral PDS[™] Plus Knotless Tissue Control Device will be available as a suture product with IRGACARE ®^{*} MP, an antibacterial agent.

Substantial Equivalence:

STRATAFIXTM Spiral PDSTM Plus Knotless Tissue Control Device has the same intended use and similar indications for use as the predicate devices. The technological differences between the subject device, STRATAFIXTM Spiral PDSTM Plus Knotless Tissue Control Device and the predicate devices raise no new questions of safety or effectiveness. STRATAFIXTM Spiral PDSTM Plus Knotless Tissue Control Device met all testing criteria to demonstrate substantial equivalence to the predicates devices.

Conclusion:

Based on the intended use, technological characteristics, safety and performance testing STRATAFIXTM Spiral PDSTM Plus Knotless Tissue Control Device has been shown to be appropriate for its intended use and is considered to be substantially equivalent to the predicate devices.

* Trademark

IRGACARE®* MP (triclosan) "Registered Trademark of BASF Group"